316 studies found for:    CLL [CONDITION] | Open Studies
Show Display Options
Rank Status Study
1 Unknown  Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)
Conditions: Chronic Lymphocytic Leukemia;   CLL;   Untreated;   Front-line;   First-Line;   Initial Therapy
Intervention: Drug: Lenalidomide and Rituximab
2 Recruiting Natural Killer Cells and Bortezomib to Treat Cancer
Conditions: Lung or Prostatic Neoplasms;   Colorectal or Kidney Neoplasms;   Pancreatic Neoplasms;   Leukemia, Myelogenous, Chronic Lymphocytic Leukemia, BCR-ABL Positive;   Melanoma;   CLL
Intervention: Drug: NK cells +CliniMACs CD3 and CD56 systems
3 Recruiting A Retrospective Study to Assess the Efficacy and Safety of Chlorambucil Plus Rituximab in CLL Paients and Safety of Chlorambucil Plus Rituximab as Front-line Therapy in Elderly and/or Unfit Patients Affected by B-cell Chronic Lymphocytic Leukemia
Conditions: CLL;   B-cell;   Small Lymphocytic Lymphoma;   Untreated B-CLL;   Elderly Patients
Intervention:
4 Unknown  Multi-center Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Conditions: Chronic Lymphocytic Leukemia;   CLL
Interventions: Drug: Revlimid, rituximab;   Drug: Relapsed or refractory CLL. Lenalidomide and Rituximab
5 Recruiting A Phase II Study of Ofatumumab-Based Induction Chemoimmunotheraphy Followed by Consolidation Ofatumumab Immunotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Conditions: Small Lymphocytic Lymphoma;   CLL (Chronic Lymphocytic Leukemia)
Interventions: Drug: Fludarabine Phosphate;   Biological: Ofatumumab;   Drug: Cyclophosphamide
6 Recruiting Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL
Conditions: Contiguous Stage II Small Lymphocytic Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Prolymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Stage I Chronic Lymphocytic Leukemia;   Stage I Small Lymphocytic Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage III Small Lymphocytic Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Small Lymphocytic Lymphoma
Interventions: Biological: MOR00208;   Drug: lenalidomide;   Other: Correlative Studies
7 Recruiting Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL)
Conditions: Chronic Lymphocytic Leukemia (CLL);   Small Lymphocytic Lymphoma;   Leukemia, Prolymphocytic
Intervention: Drug: auranofin
8 Recruiting Lenalidomide Plus Bendamustine and Rituximab for Untreated CLL/SLL
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   B Chronic Lymphocytic Leukemia
Interventions: Drug: Lenalidomide;   Drug: Bendamustine;   Drug: Rituximab
9 Recruiting Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)
Conditions: Chronic Lymphocytic Leukemia (CLL);   Small Lymphocytic Lymphoma (SLL)
Intervention: Drug: Bendamustine and Rituximab induction with Rituximab and Lenalidomide Maintenance
10 Unknown  Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in 17p- Chronic Lymphocytic Leukemia (CLL)
Condition: CLL
Intervention:
11 Recruiting Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL
Conditions: Non-hodgkin's Lymphoma;   Follicular Lymphoma;   Mantle Cell Lymphoma;   Marginal Zone Lymphoma;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Intervention: Drug: IMMU-114
12 Recruiting Phase I Study of B Cell Malignancies Using T Cells Expressing an Anti-CD19 Chimeric Receptor: Assessment of the Impact of Lymphocyte Depletion Prior to T Cell Transfer
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Mantle Cell Lymphoma;   Follicular Lymphoma;   Large Cell Lymphoma
Interventions: Drug: Fludarabine;   Drug: Cyclophosphamide;   Biological: Anti-CD19-CAR PBL
13 Recruiting Vaccine Therapy for Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Condition: Chronic Lymphocytic Leukemia (CLL)
Intervention: Biological: Oncoquest-CLL vaccine
14 Recruiting Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL
Conditions: CLL;   SLL
Interventions: Drug: Ofatumumab;   Drug: High-Dose Methylprednisolone;   Drug: Alemtuzumab
15 Recruiting A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphoma
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Interventions: Drug: Rituximab;   Drug: Ibrutinib
16 Recruiting Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory CLL
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Intervention: Drug: Lenalidomide, Ibrutinib, Rituximab
17 Recruiting Phase II Ofatumumab/Methylprednisolone Followed by Ofatumumab/Lenalidomide for Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Interventions: Drug: High Dose Methylprednisolone (HDMP);   Drug: Ofatumumab;   Drug: Lenalidomide
18 Recruiting Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Interventions: Drug: dasatinib;   Drug: Rituximab;   Drug: fludarabine
19 Recruiting Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion
Condition: B-cell Chronic Lymphocytic Leukemia (CLL) With 17p Deletion
Interventions: Drug: Idelalisib;   Drug: Rituximab
20 Recruiting A Phase 3 Extension Study of IPI-145 and Ofatumumab in Patients With CLL/SLL Previously Enrolled in Study IPI-145-07
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Interventions: Drug: IPI-145;   Drug: Ofatumumab

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years